Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
According to Biogen's latest financial reports the company's total debt is ยฃ4.97 Billion. A companyโs total debt is the sum of all current and non-current debts.
Year | Total debt | Change |
---|---|---|
2024-12-31 | ยฃ5.28 B | -8.27% |
2023-12-31 | ยฃ5.75 B | 5.36% |
2022-12-31 | ยฃ5.46 B | -2.94% |
2021-12-31 | ยฃ5.63 B | -1.92% |
2020-12-31 | ยฃ5.74 B | 18.27% |
2019-12-31 | ยฃ4.85 B | 3.83% |
2018-12-31 | ยฃ4.67 B | 6.44% |
2017-12-31 | ยฃ4.39 B | -16.82% |
2016-12-31 | ยฃ5.28 B | 19.94% |
2015-12-31 | ยฃ4.40 B | 1075.27% |
2014-12-31 | ยฃ0.37 B | 3.73% |
2013-12-31 | ยฃ0.36 B | -48.82% |
2012-12-31 | ยฃ0.70 B | 3.1% |
2011-12-31 | ยฃ0.68 B | -12.19% |
2010-12-31 | ยฃ0.77 B | 14.69% |
2009-12-31 | ยฃ0.67 B | -10.5% |
2008-12-31 | ยฃ0.75 B | -3.47% |
2007-12-31 | ยฃ0.78 B | 1493.75% |
2006-12-31 | ยฃ49.36 M | 95.95% |
2005-12-31 | ยฃ25.19 M | -94.31% |
2004-12-31 | ยฃ0.44 B | -10.7% |
2003-12-31 | ยฃ0.49 B | -8.19% |
2002-12-31 | ยฃ0.54 B | 1560.02% |
2001-12-31 | ยฃ32.54 M | -55.57% |
2000-12-31 | ยฃ73.24 M | 4.68% |
1999-12-31 | ยฃ69.97 M | 44.84% |
1998-12-31 | ยฃ48.3 M | -13.32% |
1997-12-31 | ยฃ55.73 M | 44% |
1996-12-31 | ยฃ38.7 M |